Related coverage linked through entity extraction aliases.
Mar 27, 2026
AbbVie has received a "Moderate Buy" consensus rating from analysts with an average price target of $253.15. The company reported strong quarterly earnings of $2.71 EPS and $16.62 billion revenue, beating estimates. Recent clinical progress includes positive Phase 1 results for an obesity drug candidate showing 7.8-9.8% weight loss.
Mar 26, 2026
Morgan Stanley raised its Novartis price target to $170 from $143 with an Overweight rating, while TD Cowen increased its target to $180 from $160 with a Hold rating. Morgan Stanley sees $23 billion in risk-adjusted potential from nine pipeline assets, with additional upside in success scenarios.
Mar 16, 2026
Multiple institutional investors expanded their positions in AstraZeneca during the third quarter of 2025, with several funds increasing holdings by over 100% according to SEC filings.
Feb 28, 2026
Johnson & Johnson stock hit an all-time high of $246.54, up 54.05% over the past year. The company announced a $1 billion investment in a Pennsylvania cell therapy facility and received upgraded price targets from major financial firms.
Feb 20, 2026
FDA Commissioner Marty Makary identified hospital contracting, IRB processes, and IND application timelines as key bottlenecks slowing US early-phase trials. China now conducts more clinical trials than the US and accounts for nearly a third of new global drug approvals.
Feb 25, 2026
Medtronic's diabetes unit MiniMed is seeking up to $7.86 billion valuation in its U.S. IPO while cutting 81 jobs at its Northridge facility ahead of the planned separation into a standalone publicly traded company.
Feb 17, 2026
Two financial services firms raised their price targets for Moderna in mid-February 2026, with RBC Capital increasing its target to $30 and Evercore ISI Group raising its target to $35, both maintaining neutral ratings.
Feb 14, 2026
Multiple institutional investors modified their positions in AstraZeneca during the third quarter, with new stakes and adjustments reported in SEC filings. The company announced a dividend of $1.595 per share payable March 23rd.
Feb 12, 2026
AbbVie reported stronger-than-expected Q4 revenue of $16.62 billion and EPS of $2.71, beating consensus estimates. The company advanced a toxin-based therapy in Phase 2 trials and filed suit challenging Medicare drug-price negotiations for Botox.
